SAN RAFAEL, Calif., July 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, August 4, at 4:30 p.m. ET to discuss second quarter 2020 financial results and provide a general business update.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

Dial-in Number 
U.S. / Canada Dial-in Number: (866) 502-9859
International Dial-in Number: (574) 990-1362
Conference ID: 3285215

Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 3285215

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare genetic diseases. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.  For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Contacts: 


Investors

Media

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-host-second-quarter-2020-financial-results-conference-call-and-webcast-on-tuesday-august-4-at-430pm-et-301096822.html

SOURCE BioMarin Pharmaceutical Inc.

Copyright 2020 PR Newswire

BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more BioMarin Pharmaceutical Charts.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more BioMarin Pharmaceutical Charts.